Claims for Patent: 8,420,780
✉ Email this page to a colleague
Summary for Patent: 8,420,780
Title: | Mutated netrin 4, fragments thereof and uses thereof as drugs |
Abstract: | Proteins having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, or fragments of said sequences are provided. The protein fragments are represented by the sequences of SEQ ID NO: 2q, q varying from 3 to 36, and the sequences of SEQ ID NO: 185 to SEQ ID NO: 209. Nucleotide sequences coding for said proteins are also provided. |
Inventor(s): | Plouet; Jean (Paris, FR), Leconte; Laurence (Antony, FR), Lejmi; Esma (Issy les Moulineaux, FR) |
Assignee: | INSERM (Institut National de la Sante et de la Recherche Medicale) (Paris, FR) Centre National de la Recherche Scientifique (Paris, FR) IVS Institut des Vaisseaux et du Sang (Paris, FR) |
Application Number: | 12/523,074 |
Patent Claims: | 1. An isolated fragment of a Netrin 4 protein, said fragment consisting of the amino acid sequence selected from the group consisting of: SEQ ID NO: 8, SEQ ID NO: 10,
SEQ ID NO: 56, SEQ ID NO: 74, SEQ ID NO: 116, SEQ ID NO: 193, SEQ ID NO: 197, SEQ ID NO: 199, SEQ ID NO: 201, SEQ ID NO: 204, SEQ ID NO: 206, SEQ ID NO: 207 and SEQ ID NO: 208.
2. A pharmaceutical composition comprising: the isolated fragment of a Netrin 4 protein according to claim 1; and a pharmaceutically acceptable vehicle. 3. A combination product comprising: the isolated fragment of a Netrin 4 protein according to claim 1; and an anti-angiogenic agent selected from the group consisting of: an anti-VEGF agent, bevacizumab, pegaptanib, ranibizumab, sunitinib, sorafenib, humanized antibodies against neuropiline-1, humanized antibodies against DLL4, AM 386, and agents interfering with an angiopoietin pathway. 4. A pharmaceutical composition comprising pericytes or vascular smooth muscle cells, in association with the isolated fragment of a Netrin 4 protein according to claim 1. |
Details for Patent 8,420,780
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2027-01-19 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 06/30/2006 | ⤷ Try a Trial | 2027-01-19 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 08/10/2012 | ⤷ Try a Trial | 2027-01-19 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.